FindTrial
Sign In

Optimizing of blood sugar control for surgical patients with diabetes type 2.

Optimizing of glycemic control for surgical patients with diabetes type 2.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-002936-26-DK
Enrollment
Unknown
Registered
2014-02-28
Start date
2014-03-31
Completion date
Unknown
Last updated
2015-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 2. MedDRA version: 16.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861

Interventions

Trade Name: Lantus Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: INSULIN GLARGINE CAS Number: 160337-95-1 Concentration unit: IU international unit(s) Co

Sponsors

Christoffer Hedetoft
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age: 18-80. Type 2 diabetes. p-glucose above 15 mmol during the first 24h of hospitalization. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 59 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 59

Exclusion criteria

Exclusion criteria: Type 1 diabetes.

Design outcomes

Primary

MeasureTime frame
Main Objective: p-glucose.;Secondary Objective: Not applicable.;Primary end point(s): p-glucose: 8-11 mmol;Timepoint(s) of evaluation of this end point: 3 mnd—

Secondary

MeasureTime frame
Secondary end point(s): Non.;Timepoint(s) of evaluation of this end point: Non.—

Countries

Denmark

Contacts

Public ContactKøge Sygehus

Christoffer Hedetoft

chg@regionsjaelland.dk

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026